CTLA4 and hepatocellular carcinoma: Moreover, the results obtained previously with anti-CTLA-4 antibody use in patients with advanced hepatocellular carcinoma (Duffy et al., 2017) encouraged the use of a combination of anti-CTLA-4 and anti-PD-1 antibodies with the pan-HDACi, belinostat (Llopiz et al., 2019).